| Title |
A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia
|
|---|---|
| Published in |
Psychopharmacology, March 2013
|
| DOI | 10.1007/s00213-013-3064-2 |
| Pubmed ID | |
| Authors |
Maryam Noroozian, Sina Ghasemi, Seyed-Mohammad-Reza Hosseini, Amirhossein Modabbernia, Mohammad-Reza Khodaie-Ardakani, Omid Mirshafiee, Mehdi Farokhnia, Masih Tajdini, Farzin Rezaei, Bahman Salehi, Mandana Ashrafi, Habibeh Yekehtaz, Mina Tabrizi, Shahin Akhondzadeh |
| Abstract |
A growing body of evidence illustrates that 5-HT3 receptor antagonist drugs may be of benefit in the treatment of negative symptoms in schizophrenia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 56 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 18% |
| Researcher | 9 | 16% |
| Other | 7 | 12% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 12 | 21% |
| Unknown | 9 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 28% |
| Psychology | 8 | 14% |
| Neuroscience | 7 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 15 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2017.
All research outputs
#5,434,442
of 25,708,267 outputs
Outputs from Psychopharmacology
#1,307
of 5,353 outputs
Outputs of similar age
#43,759
of 211,398 outputs
Outputs of similar age from Psychopharmacology
#17
of 64 outputs
Altmetric has tracked 25,708,267 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,353 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,398 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.